The product was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest. It is an extracellular plant cysteine proteinase similar to papain in specificity.
<0.001 EU per 1 μg of the peptide by the LAL method
The product is indicated for the development of chemonucleolysis which is used for the digestion of the nucleus pulposus in patients with disc herniation confirmed by myelography. A disc herniation occurs when the outer portion of the spinal disc breaks down and the inner portion (nucleus pulposus) leaks out pressing surrounding nerves and leading to irradiating pain. The chemonucleolysis is a non-surgical treatment that involves the injection of an enzyme to dissolve the nucleus pulposus.
Examples of Clinical Use:
The first studies showed that after intradiscal injection of the product the effect involved the removal of the nucleus pulposus leaving the annulus intact. The clinical reports indicated a spontaneous remission of symptoms after the administration of the product. It is also highly documented an increased urinary excretion of glycosaminoglycans.
Mechanism of action:
Chymopapain is thought to degrade proteoglycan content of the intervertebral disc causing loss of glycosaminoglycan and water. This effect will cause the shrinkage of the disc and a reduction of the pressure on the nerve root.
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products
without prior written approval from Creative BioMart.
For more information on how our products could help advance your project, please contact us.